Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q4 2016 · 10-K
Revenue$63.54M$63.54M−17.4% vs Q4 2015 Net Income-$2.74M-$2.74MN/M vs Q4 2015 EPS Diluted-$0.06-$0.06N/M vs Q4 2015 Gross Profit$19,961,000−39.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$14,006,000+326.1% Free Cash Flowderived$8,669,000N/M Margins · derivedGross margin31.4%−11.7 pt vs Q4 2015
Operating margin-7.6%−26.3 pt vs Q4 2015
Net margin-4.3%−14.1 pt vs Q4 2015
ended Dec 31, 2016 · filed Mar 15, 2017 · 74 d after period end